INTRODUCTION. DISCUSSION. MILLIMETER WAVE TREATMENT IS INCOMPATIBLE WITH ORAL KETAMINE IN EXPERIMENTAL MODEL OF NEUROPATHIC PAIN IN MICE . A . Radzievsky, O . Gordiienko , S. Alekseev and M.Ziskin . Center for Biomedical Physics, Temple University School of Medicine, Philadelphia .
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
MILLIMETER WAVE TREATMENT IS INCOMPATIBLE WITH ORAL KETAMINE IN EXPERIMENTAL MODEL OF NEUROPATHIC PAIN IN MICE
A. Radzievsky, O. Gordiienko, S. Alekseev and M.Ziskin.
Center for Biomedical Physics, Temple University School of Medicine, Philadelphia
Millimeter Wave Treatment (MWT) is based on the systemic effects following local skin exposure to low power electromagnetic waves of millimeter range. In our previous experiments we have determined that MWT-induced hypoalgesia is a specific and reproducible phenomenon that involves the peripheral and central nervous systems, as well as endogenous opioids. MWT was effective in suppressing acute, chronic non-neuropathic, and chronic neuropathic types of pain. The effect was power- and frequency-dependent. In the present set of experiments, to potentiate antinociception effect of the treatment for the most resistant to conventional treatment neuropathic pain, MWT was combined with different doses of oral ketamine (a non-competitive NMDA receptor antagonist, which was also shown to suppress neuropathic pain).
NMDA receptor antagonists are rather effective therapeutic agents for the treatment of experimentally induced and clinical neuropathic pain conditions. However, NMDA receptors, nicotinic and muscarinic receptors (that also have been shown to interact with the most commonly used NMDA blocker Ketamine) are widely distributed in the CNS, and usage of this group of drugs in the treatment of neuropathic pain is limited because of their side effects (disturbances of cognition and mood). By administration of Ketamine per os we reduced possible side effects of the treatment. Only at the largest dose of Ketamine (100 mg/kg) did we observe some aggravation of neuropathic pain symptoms in the first 5 days following the treatment.
Considering that MWT mostly acts through opioid receptor mechanisms, and Ketamine – by blocking NMDA receptors, we anticipated synergetic effect of the combined treatment. However, the results of the experiments were opposite. Both treatments significantly decreased the level of neuropathic pain in mice if applied separately: Ketamine (most effectively in the dosage of 50 mg/kg) during the treatment, and MWT – in the post-treatment period. But, when used together, the treatments canceled each other. Furthermore, when MWT was combined with 50 or 100 mg/kg of Ketamine, the level of neuropathic pain in experimental animals significantly increased. We concluded that Ketamine treatment should be considered as a contraindication for MWT.
Wire Surface Test
Dynamic of IIPD during and after the treatment with MW and Ketamine
Activation of nociceptive transducers in the presence of tissue damage
(Typically < 1 month)
Pain initiated or caused by a
primary lesion or dysfunction
in the nervous system
Pain persisting > 1 month or
recurring for > 3 months
Disease by itself
Symptom of traumas or various diseases
Number of times the animal is taking a vertical position.
MATERIALS AND METHODS
of Pain and
Animals:Swiss-Webster mice; 18-20 gr at the beginning of the experiment
Experimental model of neuropathic pain: Unilateral Chronic Constriction Injury of the common sciatic nerve
IIPD= hPPM x 0.141 + vPPM x 0.095 + TT x 0.083 – VA x 0.011
Ketamine - a non-competitive NMDA receptor antagonist
“When first and second-line drugs such as opioids, anticonvulsants,
or antidepressants fail to provide satisfactory analgesia for the patient with chronic pain, third-line drugs such as ketamine may provide a suitable option”
Pain signal transmission in the spinal cord
From G.Hocking et al, Anesth.& Analg., 2003
NK1-R - Neurokinin1
CCK - Cholecystokinin
Op.-R - Opiate receptor
Glu - Glutamate
SP - Substance P
Morphological changes in 30 days after surgery
2 ligatures (10-0; Alcon) tied loosely around the nerve
Ketamine (non-competitive NMDA receptor antagonist) was administered for 10 consecutive days, starting from day 13 after the surgery The following doses of Ketamine were used: 1, 10, 50, and 100 mg/kg in 0.2 of H20 via gavage.
Millimeter Wave Treatment
Time-schedule of experiments
1. CCI + Sham MWT Starting from the day 13 after the CCI, once a day, for 10 days animals were restrained for 15 min, but not exposed to MW
2. CCI + MWT10 times, once a day, mice were exposed to MW only
3. CCI + Ket1For 10 days, once a day, mice were treated with 1 mg/kg of oral Ketamine only
4. CCI + Ket1010 mg/kg of oral Ketamine
5. CCI + Ket5050 mg/kg of Ketamine
6. CCI + Ket100100 mg/kg of Ketamine
7. CCI + Ket1 + MWTIn addition to MWT, mice were treated with 1 mg/kg of oral Ketamine
8. CCI + Ket10 + MWT
9. CCI + Ket50 + MWT
10.CCI + Ket100 + MWT
Obligatory “blind” experimental settings:
Grant PO1 - AT002025.
Two researchers perform the test: One exposes the mice and records the tests, and the other analyzes the WST recordings
Max ΔT during 15 min of exposure = 1.2 OC